Skip to main content
XORTX Therapeutics Inc. logo

XORTX Therapeutics Inc. — Investor Relations & Filings

Ticker · XRTX ISIN · CA98420Q2071 LEI · 254900RAT3XZPF9F9350 US Manufacturing
Filings indexed 263 across all filing types
Latest filing 2026-05-19 Foreign Filer Report
Country CA Canada
Listing US XRTX

About XORTX Therapeutics Inc.

https://www.xortx.com/

XORTX Therapeutics Inc. is a late-stage clinical biopharmaceutical company that develops and commercializes therapies for diseases associated with aberrant purine metabolism and high serum uric acid. The company's pipeline focuses on progressive kidney diseases, including Autosomal Dominant Polycystic Kidney Disease (ADPKD), Type 2 Diabetic Nephropathy (T2DN), and Acute Kidney Injury (AKI), as well as gout. Its lead program, XRx-008, is in development for the treatment of ADPKD.

Recent filings

Filing Released Lang Actions
FORM 6-K
Foreign Filer Report
2026-05-19 English
FORM 6-K
Foreign Filer Report
2026-05-18 English
424B4
Prospectus
2026-05-15 English
FORM 6-K
Foreign Filer Report
2026-05-14 English
6-K - XORTX Therapeutics Inc. (0001729214) (Filer)
Foreign Filer Report
2026-04-21 English
6-K - XORTX Therapeutics Inc. (0001729214) (Filer)
Foreign Filer Report
2026-04-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.